Gastroenteropankreatik Nöroendokrin Tümörlerin Sistemik Tedavisinde Güncel Gelişmeler
Özet
Gastroenteropankreatik nöroendokrin tümörler (GEP-NET), primer yerleşim, histolojik grade, proliferasyon hızı, somatostatin reseptörü (SSTR) ekspresyonu ve klinik davranış açısından belirgin heterojenite gösteren neoplazilerdir. İleri evre hastalıkta tedavi seçimi; primer lokalizasyon, diferansiyasyon, hastalık seyri, tümör yükü, hormonal aktivite, SSTR durumu ve objektif yanıt gereksinimine göre bireyselleştirilir. Somatostatin analogları (SSA), moleküler hedefli tedaviler, kapesitabin-temozolomid (CAPTEM) başta olmak üzere sitotoksik kemoterapi ve peptid reseptör radyonüklid tedavisi (PRRT) güncel sistemik yaklaşımın temel bileşenleridir. Son yıllarda NETTER-2, SSTR-pozitif yüksek G2 ve G3 GEP-NET’lerde PRRT’nin daha erken basamaklarda değerlendirilebileceğini göstermiş; CABINET, daha önce tedavi edilmiş pankreatik ve ekstrapankreatik NET’lerde kabozantinib için faz III kanıt sağlamıştır. 2026’da yayımlanan OCLURANDOM, önceden tedavi görmüş SSTR-pozitif progresif pankreatik NET’lerde 177Lu-DOTATATE ve sunitinibi randomize, açık etiketli, karşılaştırmalı olmayan faz II bir tasarımda değerlendirmiş; COMPETE faz III çalışması ise SSTR-pozitif G1–G2 GEP-NET’lerde 177Lu-edotreotide ile everolimusu doğrudan karşılaştırmıştır. Bu bölümde sistemik tedavi seçenekleri, hasta ve tümör özelliklerine göre tedavi seçimi, iyi diferansiye G3 NET yaklaşımı ve tedavi sekanslaması medikal onkoloji pratiği açısından değerlendirilmektedir.
Referanslar
So E, Morizane C, Okusaka T. Systemic therapy for gastroenteropancreatic neuroendocrine neoplasms: current landscape and future directions. Therapeutic Advances in Medical Oncology. 2026;18:17588359261471127. doi:10.1177/17588359261471127
Vijayvergia N, Lee LS, Katona BW. Gastroenteropancreatic neuroendocrine tumors. Gastroenterology. 2026;170(1):34–49. doi:10.1053/j.gastro.2025.07.004
Del Rivero J, Perez K, Kennedy EB, et al. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. Journal of Clinical Oncology. 2023;41(32):5049–5067. doi:10.1200/JCO.23.01529
Singh S, Halperin D, Myrehaug S, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. The Lancet. 2024;403(10446):2807–2817. doi:10.1016/S0140-6736(24)00701-3
Chan JA, Geyer S, Zemla T, et al. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. New England Journal of Medicine. 2025;392(7):653–665. doi:10.1056/NEJMoa2403991
McNamara MG, Sorbye H, Begum N, et al. Controversies in NEN: An ENETS position statement on the treatment of patients with Grade 3 well-differentiated neuroendocrine tumours of the gastro-enteropancreatic tract. Journal of Neuroendocrinology. 2025;37(12):e70080. doi:10.1111/jne.70080
Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology. 2009;27(28):4656–4663. doi:10.1200/JCO.2009.22.8510
Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. New England Journal of Medicine. 2014;371(3):224–233. doi:10.1056/NEJMoa1316158
Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine. 2011;364(6):514–523. doi:10.1056/NEJMoa1009290
Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. The Lancet. 2016;387(10022):968–977. doi:10.1016/S0140-6736(15)00817-X
Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New England Journal of Medicine. 2011;364(6):501–513. doi:10.1056/NEJMoa1003825
U.S. Food and Drug Administration. FDA approves cabozantinib for adults and pediatric patients 12 years of age and older with pNET and epNET. [Internet]. 2025 Mar 26. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cabozantinib-adults-and-pediatric-patients-12-years-age-and-older-pnet-and-epnet [Erişim: 28 Eylül 2026]
Kunz PL, Graham NT, Catalano PJ, et al. Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). Journal of Clinical Oncology. 2023;41(7):1359–1369. doi:10.1200/JCO.22.01013
Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. New England Journal of Medicine. 2017;376(2):125–135. doi:10.1056/NEJMoa1607427
Baudin E, Durand A, Beron A, et al. [177Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trial. The Lancet Oncology. 2026;27(6):699–710. doi:10.1016/S1470-2045(26)00108-7
Walter T, Jann H, Ansquer C, et al. [177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial. The Lancet. 2026;408(10551):234–247. doi:10.1016/S0140-6736(26)00604-5
Strosberg JR, Caplin ME, Kunz PL, et al. [177Lu]Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. The Lancet Oncology. 2021;22(12):1752–1763. doi:10.1016/S1470-2045(21)00572-6
Chauhan A, Halfdanarson TR, Vijayvergia N. Sequencing Choices and Real-World Clinical Management in Advanced Grade 2/3 GEP-NET Treatment: The Emerging Role of PRRT. Cancers. 2025;17(18):3008. doi:10.3390/cancers17183008
Virgolini IJ, Di Santo G, Santo G. Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directions. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(7):4335–4347. doi:10.1007/s00259-025-07750-w